Evidence map›Paper›PMID 21304052›Full record

ArticleCarcinogenesis2011

Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells.

Benjamin A T Rodriguez, Yu-I Weng, Ta-Ming Liu, Tao Zuo, Pei-Yin Hsu, Ching-Hung Lin, Ann-Lii Cheng, Hengmi Cui, Pearlly S Yan, Tim H-M Huang

Open access · bronzeAbstract read
In one paragraph

Article in Carcinogenesis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Reply to Suresh.American journal of physiology. Lung cellular and molecular physiology · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Benjamin A T RodriguezHuman Cancer Genetics Program, Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA.
Yu-I Weng
Ta-Ming Liu
Tao Zuo
Pei-Yin Hsu
Ching-Hung Lin
Ann-Lii Cheng
Hengmi Cui
Pearlly S Yan
Tim H-M Huang
The Ohio State University · USNational Taiwan University Hospital · TWJohns Hopkins Medicine · US

Funding

Predicting Drug Resistance in Cancer Genomes by DMA Methylation ProfilingU54CA113001 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HUANG, TIM H.-M. · 2004 to 2014
$16.1M
DNA Hypermethylation in Breast CancerR01CA069065 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HUANG, TIM H.-M. · 2002 to 2011
$2.4M
Epigenomics of Bisphenol A Exposure and Disease RiskR01ES017594 · NIEHS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HUANG, TIM H.-M. · 2009 to 2013
$1.8M
Environmental Epigenetics and Stem/Progenitor Cell InjuryU01ES015986 · NIEHS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HUANG, TIM H.-M. · 2007 to 2010
$1.5M
NCI NIH HHS R01CA069065NCI NIH HHS U54CA113001NIEHS NIH HHS R01ES017594NIEHS NIH HHS U01ES015986
6 · The paper itself

Abstract

While tumor suppressor genes frequently undergo epigenetic silencing in cancer, how the instructions directing this transcriptional repression are transmitted in cancer cells remain largely unclear. Expression of cyclin-dependent kinase inhibitor 1C (CDKN1C), an imprinted gene on chromosomal band 11 p15.5, is reduced or lost in the majority of breast cancers. Here, we report that CDKN1C is suppressed by estrogen through epigenetic mechanisms involving the chromatin-interacting noncoding RNA KCNQ1OT1 and CCCTC-binding factor (CTCF). Activation of estrogen signaling reduced CDKN1C expression 3-fold (P < 0.001) and established repressive histone modifications at the 5' regulatory region of the locus. These events were concomitant with induction of KCNQ1OT1 expression as well as increased recruitment of CTCF to both the distal KCNQ1OT1 promoter-associated imprinting control region (ICR) and the CDKN1C locus. Transient depletion of CTCF by small interfering RNA increased CDKN1C expression and significantly reduced the estrogen-mediated repression of CDKN1C. Further studies in breast cancer cell lines indicated that the epigenetic silencing of CDKN1C occurs in part as the result of genetic loss of the inactive methylated 11p15.5 ICR allele (R(2) = 0.612, P < 0.001). We also found a novel cis-encoded antisense transcript, CDKN1C-AS, which is induced by estrogen signaling following pharmacologic inhibition of DNA methyltransferase and histone deacetylase activity. Forced expression of CDKN1C-AS was capable of repressing endogenous CDKN1C in vivo. Our findings suggest that in addition to promoter hypermethylation, epigenetic repression of tumor suppressor genes by CTCF and noncoding RNA transcripts could be more common and important than previously understood.

Indexed as

DNA MethylationGenomic ImprintingBreast NeoplasmsCCCTC-Binding FactorChromatin ImmunoprecipitationCyclin-Dependent Kinase Inhibitor p57Epigenesis, GeneticEstrogensFemaleGene Expression Regulation, NeoplasticGene SilencingHumansPotassium Channels, Voltage-GatedPromoter Regions, GeneticRepressor ProteinsReverse Transcriptase Polymerase Chain ReactionCCCTC-Binding FactorCDKN1C protein, humanCTCF protein, humanCyclin-Dependent Kinase Inhibitor p57EstrogensKCNQ1OT1 long non-coding RNA, humanPotassium Channels, Voltage-GatedRepressor ProteinsRNA, MessengerRNA, Untranslated

Identifiers

PMID21304052
PMCPMC3106431
OpenAlexW2115251481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.